| Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion RD Schreiber, LJ Old, MJ Smyth Science 331 (6024), 1565-1570, 2011 | 7571 | 2011 |
| Cancer immunoediting: from immunosurveillance to tumor escape GP Dunn, AT Bruce, H Ikeda, LJ Old, RD Schreiber Nature immunology 3 (11), 991-998, 2002 | 7045 | 2002 |
| How cells respond to interferons GR Stark, IM Kerr, BRG Williams, RH Silverman, RD Schreiber Annual review of biochemistry 67 (1), 227-264, 1998 | 5262 | 1998 |
| Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death D Hockenbery, G Nuņez, C Milliman, RD Schreiber, SJ Korsmeyer Nature 348 (6299), 334-336, 1990 | 5199 | 1990 |
| Neoantigens in cancer immunotherapy TN Schumacher, RD Schreiber Science 348 (6230), 69-74, 2015 | 5137 | 2015 |
| The three Es of cancer immunoediting GP Dunn, LJ Old, RD Schreiber Annu. Rev. Immunol. 22 (1), 329-360, 2004 | 4145 | 2004 |
| IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity V Shankaran, H Ikeda, AT Bruce, JM White, PE Swanson, LJ Old, ... Nature 410 (6832), 1107-1111, 2001 | 4135 | 2001 |
| The immunobiology of cancer immunosurveillance and immunoediting GP Dunn, LJ Old, RD Schreiber Immunity 21 (2), 137-148, 2004 | 3946 | 2004 |
| Metabolic competition in the tumor microenvironment is a driver of cancer progression CH Chang, J Qiu, D O’Sullivan, MD Buck, T Noguchi, JD Curtis, Q Chen, ... Cell 162 (6), 1229-1241, 2015 | 2899 | 2015 |
| Natural innate and adaptive immunity to cancer MD Vesely, MH Kershaw, RD Schreiber, MJ Smyth Annual review of immunology 29 (1), 235-271, 2011 | 2756 | 2011 |
| Batf3 deficiency reveals a critical role for CD8α+ dendritic cells in cytotoxic T cell immunity K Hildner, BT Edelson, WE Purtha, M Diamond, H Matsushita, ... Science 322 (5904), 1097-1100, 2008 | 2267 | 2008 |
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens MM Gubin, X Zhang, H Schuster, E Caron, JP Ward, T Noguchi, Y Ivanova, ... Nature 515 (7528), 577-581, 2014 | 2223 | 2014 |
| Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice DH Kaplan, V Shankaran, AS Dighe, E Stockert, M Aguet, LJ Old, ... Proceedings of the national academy of sciences 95 (13), 7556-7561, 1998 | 2116 | 1998 |
| Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK–STAT signaling pathway MA Meraz, JM White, KCF Sheehan, EA Bach, SJ Rodig, AS Dighe, ... Cell 84 (3), 431-442, 1996 | 2093 | 1996 |
| The molecular cell biology of interferon-gamma and its receptor MA Farrar, RD Schreiber Annual review of immunology 11 (1), 571-611, 1993 | 1994 | 1993 |
| Interferons, immunity and cancer immunoediting GP Dunn, CM Koebel, RD Schreiber Nature Reviews Immunology 6 (11), 836-848, 2006 | 1976 | 2006 |
| New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape D Mittal, MM Gubin, RD Schreiber, MJ Smyth Current opinion in immunology 27, 16-25, 2014 | 1934 | 2014 |
| Adaptive immunity maintains occult cancer in an equilibrium state CM Koebel, W Vermi, JB Swann, N Zerafa, SJ Rodig, LJ Old, MJ Smyth, ... Nature 450 (7171), 903-907, 2007 | 1820 | 2007 |
| The IFNγ receptor: a paradigm for cytokine receptor signaling EA Bach, M Aguet, RD Schreiber Annual review of immunology 15 (1), 563-591, 1997 | 1544 | 1997 |
| Cytokine signaling in 2002: new surprises in the Jak/Stat pathway JJ O'Shea, M Gadina, RD Schreiber Cell 109 (2), S121-S131, 2002 | 1515 | 2002 |
Matthew GubinThe University of Texas MD Anderson Cancer CenterVerified email at mdanderson.org
